Autoantibodies against p53 are not increased in human ascites and pleural effusions

• Published in: Cancer Immunology, Immunotherapy Immunotherapy, 1996-03, Vol.42 (3), p.200-201
• Main Authors: MUNKER, R, STÖTZER, O, DARSOW, M, CLASSEN, S, LEBEAU, A, WILMANNS, W
• Format: Article
• Language: English
• Subjects: Antibody Specificity; Antigens, Neoplasm - analysis; Ascites - immunology; Autoantibodies - analysis; Biological and medical sciences; Enzyme-Linked Immunosorbent Assay; Host-tumor relations. Immunology. Biological markers; Humans; Medical sciences; Pleural Effusion, Malignant - chemistry; Short Communication; Tumor Suppressor Protein p53 - immunology; Tumors
• ISSN: 0340-7004; 1432-0851
• DOI: 10.1007/s002620050271

Mutated human p53 may give rise to the formation of autoantibodies and may be a marker for a worse prognosis. We speculated that ascites or pleural effusions may enhance the formation of such autoantibodies in cancer patients and, therefore, we measured the presence of autoantibodies in the ascites or pleural effusion of 40 patients with advanced malignancies. As controls, p53 autoantibodies were measured in 15 patients with effusions who did not have a malignancy. Using a specific enzyme-linked immunosorbent assay, p53 autoantibodies could only be detected in the effusions of 5/40 patients (12.5%) with known malignancies. The formation of autoantibodies did not correlate with the presence or absence of tumor cells in the effusion. The effusions of the patients without tumor were all negative for p53 autoantibodies. Our study shows that malignant or reactive effusions do not stimulate the local or systemic production of autoantibodies against p53.